Pharmacogenetics

Definition

Pharmacogenetics, related to pharmacology, is the study of the genetic variation between individuals that affects their response to drugs/pharmaceuticals and other xenobiotics, both therapeutically and in terms of adverse effects (side effects). Personalized medicine is the use of pharmacogenetics to understand how an individual can benefit from specific drugs.

Latest Research and Reviews

  • Research | | open

    A wealth of gene expression data is publicly available, yet is little use without additional human curation. Ma’ayan and colleagues report a crowdsourcing project involving over 70 participants to annotate and analyse thousands of human disease-related gene expression datasets.

    • Zichen Wang
    • , Caroline D. Monteiro
    • , Kathleen M. Jagodnik
    • , Nicolas F. Fernandez
    • , Gregory W. Gundersen
    • , Andrew D. Rouillard
    • , Sherry L. Jenkins
    • , Axel S. Feldmann
    • , Kevin S. Hu
    • , Michael G. McDermott
    • , Qiaonan Duan
    • , Neil R. Clark
    • , Matthew R. Jones
    • , Yan Kou
    • , Troy Goff
    • , Holly Woodland
    • , Fabio M R. Amaral
    • , Gregory L. Szeto
    • , Oliver Fuchs
    • , Sophia M. Schüssler-Fiorenza Rose
    • , Shvetank Sharma
    • , Uwe Schwartz
    • , Xabier Bengoetxea Bausela
    • , Maciej Szymkiewicz
    • , Vasileios Maroulis
    • , Anton Salykin
    • , Carolina M. Barra
    • , Candice D. Kruth
    • , Nicholas J. Bongio
    • , Vaibhav Mathur
    • , Radmila D Todoric
    • , Udi E. Rubin
    • , Apostolos Malatras
    • , Carl T. Fulp
    • , John A. Galindo
    • , Ruta Motiejunaite
    • , Christoph Jüschke
    • , Philip C. Dishuck
    • , Katharina Lahl
    • , Mohieddin Jafari
    • , Sara Aibar
    • , Apostolos Zaravinos
    • , Linda H. Steenhuizen
    • , Lindsey R. Allison
    • , Pablo Gamallo
    • , Fernando de Andres Segura
    • , Tyler Dae Devlin
    • , Vicente Pérez-García
    •  & Avi Ma’ayan
  • Reviews |

    In this Review, the authors highlight the potential for efficacy genetics to drive drug development and guide treatment options. They argue for the integration of routine pharmacogenetic screening into clinical development and propose strategies for identifying efficacy loci for marketed drugs.

    • Matthew R. Nelson
    • , Toby Johnson
    • , Liling Warren
    • , Arlene R. Hughes
    • , Stephanie L. Chissoe
    • , Chun-Fang Xu
    •  & Dawn M. Waterworth
  • Reviews |

    As the numbers of available anticancer drugs and thus possible drug combinations continues to grow, determining the optimal toxicity–efficacy balance of treatment regimens becomes increasingly complex, and the utility of standard empirical approaches to optimizing drug dosing and scheduling is becoming increasingly limited. Mathematical modelling can substantially advance the development of effective treatment regimens through improved rationalization of therapeutic strategies. In this Review, the authors highlight the achievements that have been made to date in computational modelling of drug regimens, as well as the limitations of this approach. They also discuss the potential future implementation of this strategy to achieve precision medicine in oncology.

    • Dominique Barbolosi
    • , Joseph Ciccolini
    • , Bruno Lacarelle
    • , Fabrice Barlési
    •  & Nicolas André

News and Comment